Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
In development
Reference number: GID-TA10994
Expected publication date: TBC
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early January 2024 when we will write to you about how you can get involved.